Miller GJ, Miller NE. Plasma-high-density-lipoprotein concentration and development of ischaemic
Gordon DJ, Probstfield JL, Garrison RJ.
et al. High-density lipoprotein cholesterol and cardiovascular disease. Circulation.1989;79:8-15.
Stampfer MJ, Sacks FM, Salvini S.
et al. A prospective study of cholesterol, apoproteins and the risk of myocardial
infarction. N Engl J Med.1991;325:373-381.
Goldbourt U, Yaari S, Medalie JH. Isolated low HDL cholesterol as a risk factor for coronary heart disease
mortality. Arterioscler Thromb Vasc Biol.1997;17:107-113.
Kannel WB. Range of serum cholesterol values in the population developing coronary
artery disease. Am J Cardiol.1995;76:69C-77C.
Rubins HB, Robins SJ, Collins D.
et al. Distribution of lipids in 8,500 men with coronary artery disease. Am J Cardiol.1995;75:1196-1201.
Genest Jr J, McNamara JR, Ordovas JM.
et al. Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a)
abnormalities in men with premature coronary artery disease. J Am Coll Cardiol.1992;19:792-802.
Lamarche B, Despres J-P, Moorjani S.
et al. Triglycerides and HDL-cholesterol as risk factors for ischemic heart
Rubins HB, Robins SJ, Collins D.
et al. Gemfibrozil for the secondary prevention of coronary heart disease
in men with low levels of high-density lipoprotein cholesterol. N Engl J Med.1999;341:410-418.
Sacks FM, Pfeffer MA, Moye LA.
et al. The effect of pravastatin on coronary events after myocardial infarction
in patients with average cholesterol levels. N Engl J Med.1996;335:1001-1009.
The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID)
Study Group. Prevention of cardiovascular events and death with pravastatin in patients
with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med.1998;339:1349-1357.
Group of Physicians of the Newcastle upon Tyne Region. Trial of clofibrate in the treatment of ischaemic heart disease. BMJ.1971;4:767-775.
Research Committee of the Scottish Society of Physicians. Ischaemic heart disease. BMJ.1971;4:775-784.
Not Available. A co-operative trial in the primary prevention of ischaemic heart disease
using clofibrate. Br Heart J.1978;40:1069-1118.
Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA.1975;231:360-381.
Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary
Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand.1988;223:405-418.
Frick MH, Elo O, Haapa K.
et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in
middle-aged men with dyslipidemia. N Engl J Med.1987;317:1237-1245.
The BIP Study Group. Secondary prevention by raising HDL-cholesterol and reducing triglycerides
in patients with coronary artery disease: the Bezafibrate Infarction Prevention
(BIP) Study. Circulation.2000;102:21-27.
Staels B, Dallongeville J, Auwerx J.
et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation.1998;98:2088-2093.
Ponsin G, Girardot G, Berthezene F. Mechanism of the gemfibrozil-induced decrease in the transfer of cholesterol
esters from high density lipoproteins to very low and low density lipoproteins. Biochem Med Metab Biol.1994;52:58-64.
Franceschini G, Lovati MR, Manzoni C.
et al. Effect of gemfibrozil treatment in hypercholesterolemia on low density
lipoprotein (LDL) subclass distribution and LDL-cell interaction. Atherosclerosis.1995;114:61-71.
Saku K, Gartside PS, Hynd BA, Kashyap ML. Mechanism of action of gemfibrozil on lipoprotein metabolism. J Clin Invest.1985;75:1702-1712.
Fruchart J-C, Duriez P, Staels B. Peroxisome proliferator-activated receptor-alpha activators regulate
genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opin Lipidol.1999;10:245-257.
Rubins HB, Robins SJ, Iwane MK.
et al. Rationale and design of the Department of Veterans Affairs High Density
Lipoprotein Cholesterol Intervention Trial (HIT) for secondary prevention
of coronary artery disease in men with low high-density lipoprotein cholesterol
and desirable low-density lipoprotein cholesterol. Am J Cardiol.1993;71:45-52.
McNamara JR, Schaefer EJ. Automated enzymatic standardized lipid analyses for plasma and lipoprotein
fractions. Clin Chim Acta.1987;166:1-8.
Friedewald WT, Levy RI, Frederickson DS. Estimation of the concentration of low-density lipoprotein cholesterol
in plasma, without use of the preparative ultracentrifuge. Clin Chem.1972;18:499-502.
McNamara JR, Huang C, Massov T.
et al. Modification of the dextran-Mg2+ HDL cholesterol precipitation method
for use with previously frozen plasma. Clin Chem.1994;40:233-239.
Contois JH, McNamara JR, Lammi-Keefe CJ.
et al. Reference intervals for plasma apolipoprotein A-I as determined with
a commercially available immunoturbidometric assay. Clin Chem.1996;42:507-514.
Contois JH, McNamara JR, Lammi-Keefe CJ.
et al. Reference intervals for plasma apolipoprotein B as determined with
a commercially available immunoturbidometric assay. Clin Chem.1996;42:515-523.
Nguyen T, Warnick GR. Improved methods for separation of total HDL and subclasses [abstract]. Clin Chem.1989;35:1086.
Cox DR. Regression models and life-tables. J R Stat Soc B.1972;34:187-202.
Rubins HB, Robins SJ, Collins D.for the Veterans Affairs Cooperative Studies Program High-Density Lipoprotein
Intervention Trial Study Group. Baseline characteristics of normocholesterolemic men with coronary
artery disease and low levels of high-density lipoprotein cholesterol. Am J Cardiol.1996;78:572-575.
Manninen V, Elo O, Frick H.
et al. Lipid alterations and decline in the incidence of coronary heart disease
in the Helsinki Heart Study. JAMA.1988;260:641-651.
Sorisky A, Ooi TC, Simo IE.
et al. Change in composition of high density lipoprotein during gemfibrozil
Manttari M, Koskinen P, Manninen V.
et al. Effect of gemfibrozil on the concentration and composition of serum
Fielding CJ. Early events in the transfer of cell-derived cholesterol to human plasma. In: Miller NE, ed. High Density Lipoprotein and
Atherosclerosis II. Amsterdam, the Netherlands: Elsevier; 1989:149-158.
Castro Cabezas M, van Heusden GPH, de Bruin TWA.
et al. Reverse cholesterol transport: relationship between free cholesterol
uptake and HDL3 in normolipidaemic and hyperlipidaemic subjects. Eur J Clin Invest.1993;23:122-129.
Watts GF, Mandalia S, Brunt JNH.
et al. Independent associations between plasma lipoprotein subfraction levels
and the course of coronary artery disease in the St Thomas' Atherosclerosis
Regression Study (STARS). Metabolism.1993;42:1461-1467.
Syvanne M, Nieminen MS, Frick MH.
et al. Associations between lipoproteins and the progression of coronary and
vein-graft atherosclerosis in a controlled trial with gemfibrozil in men with
low baseline levels of HDL cholesterol. Circulation.1998;98:1993-1999.
Ballantyne CM, Herd A, Ferlic LL.
et al. Influence of low HDL on progression of coronary artery disease and
response to fluvastatin therapy. Circulation.1999;99:736-743.
Mack WJ, Krauss RM, Hodis HN. Lipoprotein subclasses in the Monitored Atherosclerosis Regression
Study (MARS): treatment effects and relation to coronary angiographic progression. Arterioscler Thromb Vasc Biol.1996;16:697-704.
Sehayek E, Eisenberg S. The role of native apolipoprotein B-containing lipoproteins in atherosclerosis. Curr Opin Lipidol.1994;5:350-353.
Gotto AM, Whitney E, Stein EA.
et al. Relation between baseline and on-treatment lipid parameters and first
acute major coronary events in AFCAPS/TexCAPS. Circulation.2000;101:477-484.
Blankenhorn DH, Alaupovic P, Wickham E.
et al. Prediction of angiographic change in native human coronary arteries
and aortocoronary bypass grafts. Circulation.1990;81:470-476.
Brown G, Albers JJ, Fisher LD.
et al. Regression of coronary artery disease as a result of intensive lipid-lowering
therapy in men with high levels of apolipoprotein B. N Engl J Med.1990;323:1289-1298.
Ruotolo G, Ericson CG, Tettamanti C.
et al. Treatment effects on serum lipoproteins, lipids, apolipoproteins and
low density lipoprotein particle size and relationships of lipoprotein variables
to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis
Intervention Trial (BECAIT). J Am Coll Cardiol.1998;32:1648-1656.